Quanterix Q4 revenue rises 25%
Quanterix Corporation QTRX | 3.60 3.60 | +6.19% 0.00% Post |
Overview
Biomarker detection firm's Q4 revenue rose 25% yr/yr
Company expects cash flow breakeven in 2026
Submitted FDA notification for Alzheimer's blood test
Outlook
Quanterix expects 2026 revenue of $169 to $174 mln
Company anticipates cash flow breakeven in second half of 2026
Quanterix expects to end 2026 with $100 mln in cash and no debt
Result Drivers
PRODUCT REVENUE GROWTH - Q4 revenue increased 25% yr/yr, driven by product revenue growth
COST SAVINGS - Implemented $74 mln of cost savings related to Akoya transaction, with 94% of integration milestones complete
Company press release: ID:nBw5QkcNCa
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q4 Product Revenue |
|
$29.22 mln |
|
Q4 Net Income |
|
-$23.12 mln |
|
Q4 Basic EPS |
|
-$0.49 |
|
Q4 Gross Profit |
|
$20.04 mln |
|
Q4 Operating Expenses |
|
$44.79 mln |
|
Q4 Operating Income |
|
-$24.75 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Quanterix Corp is $7.50, about 14.5% above its February 27 closing price of $6.55
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.